Venus Remedies Limited (VENUSREM) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Venus Remedies Limited stock ₹1,648, price ₹1,561, upside +5.6%, quality 74 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Venus Remedies Limited
VENUSREM · NSESolid company and rising price, but the stock is already about fairly priced: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range ₹147.75 – ₹1,947 · fair‑value band ₹1,092 – ₹2,229 · the ₹1,561 price screens below the ₹1,648 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 14, 2026.
Every Wednesday you see whether Venus Remedies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology.
Show moreShow less
The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, and solvent products, as well as herbal medicine.
The company was incorporated in 1989 and is headquartered in Panchkula, India.
Stock analysis
Venus Remedies Limited (VENUSREM) currently trades at ₹1,561, while our model-based Fair Value estimate is ₹1,648, so the stock looks roughly fairly valued today (gap 5.3%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹1,432 per share, and 3 of the 24 models we run sit above the ₹1,561 price.
Bear case: the Economic Profit group reads lowest at ₹508.43, and 21 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹1,092 (bear) to ₹2,229 (bull), the price of ₹1,561 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Venus Remedies Limited reported revenue of ₹7.7B in FY2026 versus ₹6.0B in FY2022, a compound +6.5%/yr. Reported net income was ₹1.0B in FY2026, compounding +26.0%/yr from FY2022.
Key figures
Market cap ₹20.9B (≈ $221M) Micro · P/E ratio 17.8 · P/S ratio 2.47 · EPS (TTM) ₹87.46 · Net margin 14.3% · Return on equity 16.8% · Return on assets (EBIT) 6.9% (5-year average) · Operating margin 15.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 63 out of 100 (medium confidence).
What moves the price
The share trades about 20% below its 52-week high and 181% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 6%, VENUSREM screens cheaper than that median.
Fair Value models
All 24 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch VENUSREM, get fair value alerts →
Compare Venus Remedies Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/S ratio by industry
- EBIT margin by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs VENUSREM |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs VENUSREM |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs VENUSREM |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs VENUSREM |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs VENUSREM |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs VENUSREM |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs VENUSREM |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs VENUSREM |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs VENUSREM |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs VENUSREM |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Venus Remedies Limited (VENUSREM) overvalued or undervalued?
What is the fair value of VENUSREM?
What is the quality score of VENUSREM?
What is the price target for Venus Remedies Limited (VENUSREM)?
What is the Venus Remedies Limited stock forecast for 2026?
What is the revenue of Venus Remedies Limited (VENUSREM)?
What growth is priced into Venus Remedies Limited (VENUSREM)?
What discount rate (WACC) does the fair value of VENUSREM use?
What is a reverse DCF?
How much growth has Venus Remedies Limited (VENUSREM) delivered so far?
How fast is the sector of Venus Remedies Limited (VENUSREM) growing?
What is the free cash flow yield of Venus Remedies Limited (VENUSREM)?
What is the intrinsic value of Venus Remedies Limited (VENUSREM)?
Is Venus Remedies Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of VENUSREM?
How much is Venus Remedies Limited worth?
What do the bullish and bearish scenarios say about VENUSREM?
What is the P/E ratio of VENUSREM?
How solid is the balance sheet of Venus Remedies Limited (VENUSREM)?
How far is VENUSREM from its 52-week high?
Which stocks are comparable to Venus Remedies Limited?
Is Venus Remedies Limited stock attractive at the current price?
How is the fair value of VENUSREM calculated?
Is it still worth investing in stocks now?
What is the share price of Venus Remedies Limited (VENUSREM)?
What should I pay attention to with Venus Remedies Limited right now?
Key figures of Venus Remedies Limited
How large is the market capitalisation of Venus Remedies Limited (VENUSREM)?
What is the P/S ratio of Venus Remedies Limited (VENUSREM)?
What are the earnings per share of Venus Remedies Limited (VENUSREM)?
What is the net margin of Venus Remedies Limited (VENUSREM)?
What is the return on equity of Venus Remedies Limited (VENUSREM)?
What is the EBIT return on assets of Venus Remedies Limited (VENUSREM)?
What is the operating margin of Venus Remedies Limited (VENUSREM)?
How fast is revenue growing at Venus Remedies Limited (VENUSREM)?
How fast are earnings growing at Venus Remedies Limited (VENUSREM)?
How much net cash does Venus Remedies Limited (VENUSREM) hold?
Watch Venus Remedies Limited in the live analysis
One click puts Venus Remedies Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.